Intriguingly, in AML and BPDCN cells, PI3Kγ inhibition by eganelisib or genetic loss inhibited the noncanonical substrate PAK1, but not AKT (also known as protein kinase B, PKB). Here, AKT1 is linked to acute myeloid leukemia.